Market closedNon-fractional
Verastem/VSTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
VSTM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Needham, United States
Employees
73
Website
www.verastem.com
Verastem Metrics
BasicAdvanced
$115M
Market cap
-
P/E ratio
-$4.29
EPS
0.58
Beta
-
Dividend rate
Price and volume
Market cap
$115M
Beta
0.58
Financial strength
Current ratio
4.403
Quick ratio
4.133
Long term debt to equity
109.459
Total debt to equity
113.552
Interest coverage (TTM)
-22.40%
Management effectiveness
Return on assets (TTM)
-51.55%
Return on equity (TTM)
-210.18%
Valuation
Price to book
2.97
Price to tangible book (TTM)
2.97
Price to free cash flow (TTM)
-0.773
Growth
Earnings per share change (TTM)
-3.03%
3-year earnings per share growth (CAGR)
10.34%
What the Analysts think about Verastem
Analyst Ratings
Majority rating from 8 analysts.
Verastem Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$34M
23.81%
Profit margin
0.00%
NaN%
Verastem Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.37
-$0.75
-$1.02
-$1.26
-
Expected
-$1.06
-$0.84
-$0.62
-$1.00
-$0.98
Surprise
29.25%
-11.02%
64.52%
26.42%
-
Verastem News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
Accesswire·2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
GlobeNewsWire·2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $115M as of July 27, 2024.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of July 27, 2024.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Verastem stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.